Loading...
Molecular, pathological, radiological, and immune profiling of non-brainstem pediatric high-grade glioma from the HERBY Phase II randomized trial
Abstract
The HERBY trial was a phase II open-label, randomized, multicenter trial evaluating bevacizumab (BEV) in addition to temozolomide/radiotherapy in patients with newly diagnosed non-brainstem high-grade glioma (HGG) between the ages of 3 and 18 years. We carried out comprehensive molecular analysis integrated with pathology, radiology, and immune profiling. In post-hoc subgroup analysis, hypermutator tumors (mismatch repair deficiency and somatic POLE/POLD1 mutations) and those biologically resembling pleomorphic xanthoastrocytoma (PXA]-like, driven by BRAF_V600E or NF1 mutation) had significantly more CD8+ tumor-infiltrating lymphocytes, and longer survival with the addition of BEV. Histone H3 subgroups (hemispheric G34R/V and midline K27M) had a worse outcome and were immune cold. Future clinical trials will need to take into account the diversity represented by the term "HGG" in the pediatric population. Copyright © 2018 The Author(s). Published by Elsevier Inc. All rights reserved.
Citations
Altmetric:
Date
2018
Type
Article
Subject
Bevacizumab, Chemoradiotherapy, Child, Glioma
Collections
Citation
Mackay, A., Burford, A., Molinari, V., Jones, D.T.W., Izquierdo, E., Brouwer-Visser, J., Giangaspero, F., Haberler, C., Pietsch, T., Jacques, T.S., Figarella-Branger, D., Rodriguez, D., Morgan, P.S., Raman, P., Waanders, A.J., Resnick, A.C., Massimino, M., Garre, M.L., Smith, H., Capper, D., Pfister, S.M., Wurdinger, T., Tam, R., Garcia, J., Thakur, M.D., Vassal, G., Grill, J., Jaspan, T., Varlet, P. and Jones, C. (2018) 'Molecular, Pathological, Radiological, and Immune Profiling of Non-brainstem Pediatric High-Grade Glioma from the HERBY Phase II Randomized Trial', Cancer cell, 33(5), pp. 829-842.e5. doi: https://dx.doi.org/10.1016/j.ccell.2018.04.004.
Journal / Source Title
DOI
PMID
Publisher
Cell Press